Total
0
Shares
Resverlogix - President and CEO, Donald McCaffrey (left)
President and CEO, Donald McCaffrey (left)
Source: Resverlogix
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Health Canada has approved Resverlogix’s COVID-19 Clinical Trial Application for apabetalone
  • A total of 100 patients are expected to be enrolled in the clinical study, both in Canada and abroad
  • Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor
  • Resverlogix Corp clinical-stage biotechnology company
  • Resverlogix Corp. (RVX) opened trading at C$0.86 per share

Resverlogix Corp. (RVX) is pleased to announce that Health Canada has approved the COVID-19 Clinical Trial Application for apabetalone.

The planned Phase 2 trial will be an open-label study evaluating the safety and efficacy of oral apabetalone, in combination with standard of care for patients hospitalized with COVID-19.

“Today’s exciting announcement is an important step in advancing apabetalone’s clinical development as a potentially highly effective therapeutic for COVID-19,” said Donald McCaffrey, President & CEO of Resverlogix.

“We are grateful to Health Canada for their expeditious review and approval of our application. We will continue working closely with regulators to bring apabetalone to market for the benefit of patients worldwide.”

Resverlogix plans to advance the clinical and manufacturing programs in parallel as was successfully achieved with both the Pfizer and Moderna vaccine programs. Study participants will either receive twice-daily doses of apabetalone for up to 4 weeks alongside standard of care or standard of care without apabetalone. The primary outcome of the study will be measured by the WHO Ordinal Scale for Clinical Improvement.

A total of 100 patients are expected to be enrolled, both in Canada and abroad. The enrollment is expected to begin immediately.

Apabetalone is an investigational, phase 3 clinical candidate with safety data in more than 4,000 subjects. Resverlogix has announced plans for an open-label study to assess the safety and efficacy of apabetalone in the treatment of COVID-19.

An article published in March 2020 revealed the interaction between SARS-CoV-2 (COVID-19) protein E and BET proteins. Following this finding, Resverlogix put out a call for collaborations, resulting in multiple partnerships, and initiated in-house preclinical research to further characterize and investigate apabetalone’s efficacy in treating COVID-19 infection.

The results of the collaborative research efforts have uncovered that apabetalone has the potential to combat COVID-19.

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor.

Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.

Resverlogix Corp clinical-stage biotechnology company. 

Resverlogix Corp. (RVX) opened trading at C$0.86 per share.

More From The Market Herald
Theratechnologies - Chief Medical Officer and Senior Vice President Dr. Christian Marsolais

" Theratechnologies (TSX:TH) confirms effectiveness of PDCs against vasculogenic mimicry

Theratechnologies (TH) reports its investigational peptide-drug conjugates (PDCs) are effective in inhibiting vasculogenic mimicry (VM) in ovarian and breast cancer models.

" Algernon Pharmaceuticals (CSE:AGN) receives $2M payment and applies for Nasdaq listing

Algernon Pharmaceuticals (AGN) has recently received a $2M cash payment from a refundable tax credit program for its clinical research work in Australia.

" MediPharm Labs (TSX:LABS) appoints new CEO

 MediPharm Labs (LABS) is pleased to announce that Bryan Howcroft will join MediPharm Labs as Chief Executive Officer and Director, effective November 15,

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.